Johnson & Johnson (NYSE:JNJ) Shares Unloaded Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on December 19th, the Representative disclosed that they had sold between $15,001 and $50,000 in Johnson & Johnson stock on November 20th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/26/2025.
• Sold $15,001 – $50,000 in shares of Stryker (NYSE:SYK) on 11/20/2025.
• Sold $1,001 – $15,000 in shares of Fiserv (NASDAQ:FISV) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Intercontinental Exchange (NYSE:ICE) on 9/25/2025.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $206.49 on Friday. The stock has a 50 day simple moving average of $198.10 and a 200 day simple moving average of $179.19. The stock has a market cap of $497.49 billion, a P/E ratio of 19.93, a PEG ratio of 2.24 and a beta of 0.36. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on JNJ shares. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Finally, Bank of America boosted their price target on Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Four analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $210.25.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves a subcutaneous version of Rybrevant (amivantamab) that reduces administration time from hours to minutes for EGFR?mutated NSCLC — this materially improves patient convenience, may raise uptake vs. IV therapy and supports long?term revenue potential for JNJ’s lung?cancer franchise. J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
• Positive Sentiment: FDA clears RYBREVANT FASPRO (amivantamab + hyaluronidase) as the first subcutaneous therapy across Rybrevant indications, enabling much shorter, simpler first?line regimens when combined with LAZCLUZE — a regulatory win that supports commercial uptake and margins. U.S. FDA Approval of RYBREVANT FASPRO
• Positive Sentiment: JNJ’s MedTech unit won FDA clearance for the TRUFILL n?BCA liquid embolic system to treat symptomatic chronic subdural hematoma (cSDH), expanding neurovascular indications and supporting device revenue growth. Johnson & Johnson Receives FDA Approval for TRUFILL n?BCA
• Positive Sentiment: Media and investor sentiment is bullish: Jim Cramer highlighted JNJ’s oncology momentum and broader rotation into healthcare/defensive names, which can drive retail interest and support multiple expansion. Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs
• Neutral Sentiment: Analyst/valuation commentary argues JNJ’s premium multiple is supported by accelerating growth and portfolio mix; useful context for longer?term positioning but less likely to move near?term price. Johnson and Johnson: Valuation Premium Justified By Accelerating Growth
• Neutral Sentiment: Macro note: rate cuts and dividend?friendly ETF flows (e.g., mentions in MarketBeat pieces) can support demand for high?quality dividend payers like JNJ, but impact is gradual. Rate Cuts Make These 3 Income ETFs More Attractive Than Ever
• Negative Sentiment: Near?term pullback likely driven by profit?taking after a large YTD move (shares are up significantly year?to?date); heavy volume suggests short?term selling pressure despite positive catalysts.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently modified their holdings of the business. Clark Asset Management LLC boosted its stake in Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after acquiring an additional 3,025 shares during the last quarter. Treasurer of the State of North Carolina raised its holdings in shares of Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after purchasing an additional 94,957 shares during the period. Apexium Financial LP lifted its stake in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after purchasing an additional 2,310 shares during the last quarter. Avanza Fonder AB lifted its position in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after buying an additional 6,566 shares during the last quarter. Finally, Winnow Wealth LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth $295,000. Institutional investors own 69.55% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.